DHRのチャート
DHRの企業情報
| symbol | DHR |
|---|---|
| 会社名 | Danaher Corp （DHR ダナハ―） |
| 分野（sector） | |
| 産業（industry） | |
| 業種 | 先端医療機器_テクノロジ― 医療関連（Health Care） |
| 概要 | 事業概要 ダナハー(Danaher Corporation)は専門・医療・工業・商業製品とサービスの設計・製造・販売に従事する企業。同社は四つのセグメントで事業を展開する。生命科学セグメントは病気の原因を理解し、新しい治療法を特定し、新薬とワクチンを試験するために遺伝子、タンパク質、代謝産物、細胞など、生命の基本的な構成要素の研究ツールを科学者へ提供する。診断セグメントは分析機器、試薬、消耗品、ソフトウェアおよびサービスを提供する。歯科セグメントは歯、歯肉および支持骨の疾患および病気を診断、治療および防止する製品を提供する。環境と応用ソリューションセグメントは水質と製品の識別などを含むビジネスラインから構成される。2016年12月31日現在、ダナハーはは60以上の国において、研究・開発、生産、販売、流通、サービス及び管理施設を位置する。 ダナハ―は計測装置と医療機器を扱う米国のメ―カ―。世界50カ国以上で事業を展開する。電子機器、通信ネットワ―ク機器、各種電子テストや計測装置を製造。また水質や大気質の検査、環境用の測定装置、救急診断、病理診断、ライフサイエンス研究用の関連製品、歯科用機器を提供。OEM業者向けにバ―コ―ドやスキャナ―などの製品識別なども扱う。 Danaher Corporation is a global science and technology innovator committed to helping its customers solve complex challenges and improving quality of life around the world. Its family of world class brands has leadership positions in the demanding and attractive health care, environmental and applied end-markets. With more than 20 operating companies, Danahers globally diverse team of approximately 69,000 associates is united by a common culture and operating system, the Danaher Business System, and its Shared Purpose, Helping Realize Lifes Potential. |
| 本社所在地 | 2200 Pennsylvania Avenue N.W. Suite 800W Washington DC 20037-1701 USA |
| 代表者氏名 | Steven M. Rales |
| 代表者役職名 | Chairman of the Board |
| 電話番号 | +1 202-828-0850 |
| 設立年月日 | 1969年 |
| 市場名 | NYSE（ニューヨーク証券取引所） |
| ipoyear | 年 |
| 従業員数 | 71000人 |
| url | www.danaher.com |
| nasdaq_url | |
| adr_tso | |
| EBITDA | EBITDA（百万ドル） 4711.50000 |
| 終値（lastsale） | |
| 時価総額（marketcap） | |
| 時価総額 | 時価総額（百万ドル） 94485.87000 |
| 売上高 | 売上高（百万ドル） 19893.00000 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 103438.37000 |
| 当期純利益 | 当期純利益（百万ドル） 2643.90000 |
| 決算概要 | 決算概要 BRIEF: For the fiscal year ended 31 December 2018 Danaher Corporation revenues increased 9% to $19.89B. Net income before extraordinary items increased 7% to $2.64B. Revenues reflect Life sciences segment increase of 13% to $6.47B DIAGNOSTICS segment increase of 7% to $6.26B Environmental_Applied Solutions segment increase of 9% to $4.32B All Other segment increase of 7% to $8B United States segment increase of 8% to $7.37B. |
DHRのテクニカル分析
DHRのニュース
5 Safe Stocks to Buy According to Hedge Funds 2023/02/05 13:45:23 Insider Monkey
In this article, we take a look at the 5 safe stocks to buy according to hedge funds. If you want to read our detailed analysis of safe stocks, go directly to see the 12 Safe Stocks to Buy According to Hedge Funds. 5. Danaher Corporation (NYSE:DHR) Beta Value: 0.82 Number of Hedge Fund Holders: 89 […]
Danaher said to be interested in acquiring contract manufacturer Catalent 2023/02/05 00:13:24 Seeking Alpha
Life sciences company Danaher Corporation (DHR) has expressed interest in buying the contract manufacturer Catalent (CTLT), people familiar with the matter said. Read the full story here.
Danaher interested in buying life sciences firm Catalent- Bloomberg News 2023/02/04 19:27:20 Reuters
Medical equipment maker Danaher Corp has expressed interest in taking over contract drugmaker Catalent Inc , Bloomberg News reported on Saturday, citing people familiar with the matter.
Top 5 4th Quarter Trades of PRENTISS SMITH & CO INC 2023/01/31 20:00:04 GuruFocus
Related Stocks: G , DHR , ADI , ACI , AGR ,
Top 5 4th Quarter Trades of MACKAY SHIELDS LLC 2023/01/31 16:00:05 GuruFocus
Related Stocks: DHR , AVGOP.PFD , CHRD , ACWX , AVGO ,
Genomics Market Top Players Analysis | Beijing Genomics Institute, Danaher Corporation, Oxford Nanopore Technologies, GE Healthcare and Among Others 2022/07/08 03:28:19 Benzinga
Pune, July 07, 2022 (GLOBE NEWSWIRE) -- Genomics Market by Vendor Assessment, Technology Assessment, Partner & Customer Ecosystem, type/solution, service, organization size, end-use verticals, and Region – Global Genomics Market Forecast to 2030, published by Market Data Centre, The Genomics Market is projected to grow at a solid pace during the forecast period. The presence of key players in the ecosystem has led to a compsetitive and diverse market. The advancement of digital transformation initiatives across multiple industries is expected to drive the worldwide Genomics Market during the study period. This COVID-19 analysis of the report includes COVID-19 IMPACT on the production and, demand, supply chain. This report provides a detailed historical analysis of the global Genomics Market from 2017-to 2021 and provides extensive market forecasts from 2022-to 2030 by region/country and subsectors. The report covers the revenue, sales volume, price, historical growth, and future perspectives in the Genomics Market.
Danaher Corporation – Consensus Indicates Potential 29.5% Upside 2022/07/05 10:19:52 DirectorsTalk
Danaher Corporation found using ticker (DHR) now have 18 analysts covering the stock with the consensus suggesting a rating of ''Buy''. The target price ranges between 363.4 and 265 with the average target price sitting at 328.41. Given that the stocks previous close was at 253.52 this would indicate that there is a potential upside of 29.5%. The day 50 moving average is 252.96 and the 200 day moving average is 286.31. The company has a market capitalisation of $187,622m. Find out more information at: https://www.danaher.com [stock_market_widget type="chart" template="basic" color="green" assets="DHR" range="6mo" interval="1d" axes="true" cursor="true" api="yf"] The potential market cap would be $243,046m based on the market concensus. Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company operates through three segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. The Life Sciences segment provides mass spectrometers; flow cytometry, genomics, lab automation, centrifugation, particle counting and characterization; microscopes; genomics consumables; and Gene and Cell Therapy.
Danaher Stock: A Much Needed Pullback (NYSE:DHR) 2022/07/03 09:42:27 Seeking Alpha
Danaher (DHR) is a Dividend Challenger with 8 consecutive years of dividend growth. DHR shares currently yield 0.39%. See why I am not purchasing DHR stock now.
IRW-PRESS: ACCESSWIRE News Network : OneMedNet Announces the Appointment of Dr. Christoph Zindel, Former Siemens AG and Beckman Coulter Executive, to its Board of Directors 2022/06/30 20:17:24 Boersen-Zeitung
MINNEAPOLIS, MN / ACCESSWIRE / June 30, 2022 / OneMedNet Corporation ("OneMedNet" or the "Company"), the leading curator of regulatory-grade Imaging Real Word Data, through its proven OneMedNet iRWD solution, today announced the appointment of Dr. Christoph Zindel to its Board of Directors. Dr. Zindel will be officially joining the board by October 1, 2022. Prior to his official appointment, Dr. Zindel agreed to serve on the board on a pro bono basis. Dr. Zindel, a noted industry executive, brings more than 30 years of diagnostic imaging, technology innovation, nuclear medicine and executive leadership experience and joins the board following a distinguished career including as President of Siemens Healthineers AG, where he served as Head of Diagnostic Imaging and served as a Member of the Managing Board at Siemens Healthineers AG. Currently, Dr. Zindel also serves as a Member of the Supervisory Board of Fresenius SE Group, and Senior Vice President, General Manager of Business Line Magnetic Resonance.
How Is The Market Feeling About Danaher? 2022/06/29 18:15:39 Benzinga
Danaher''s (NYSE: DHR ) short percent of float has fallen 7.35% since its last report. The company recently reported that it has 3.99 million shares sold short , which is 0.63% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.5 days to cover their short positions on average. Why Short Interest Matters Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price … Full story available on Benzinga.com
Genomics Market Top Players Analysis | Beijing Genomics Institute, Danaher Corporation, Oxford Nanopore Technologies, GE Healthcare and Among Others 2022/07/08 03:28:19 Benzinga
Pune, July 07, 2022 (GLOBE NEWSWIRE) -- Genomics Market by Vendor Assessment, Technology Assessment, Partner & Customer Ecosystem, type/solution, service, organization size, end-use verticals, and Region – Global Genomics Market Forecast to 2030, published by Market Data Centre, The Genomics Market is projected to grow at a solid pace during the forecast period. The presence of key players in the ecosystem has led to a compsetitive and diverse market. The advancement of digital transformation initiatives across multiple industries is expected to drive the worldwide Genomics Market during the study period. This COVID-19 analysis of the report includes COVID-19 IMPACT on the production and, demand, supply chain. This report provides a detailed historical analysis of the global Genomics Market from 2017-to 2021 and provides extensive market forecasts from 2022-to 2030 by region/country and subsectors. The report covers the revenue, sales volume, price, historical growth, and future perspectives in the Genomics Market.
Danaher Corporation – Consensus Indicates Potential 29.5% Upside 2022/07/05 10:19:52 DirectorsTalk
Danaher Corporation found using ticker (DHR) now have 18 analysts covering the stock with the consensus suggesting a rating of ''Buy''. The target price ranges between 363.4 and 265 with the average target price sitting at 328.41. Given that the stocks previous close was at 253.52 this would indicate that there is a potential upside of 29.5%. The day 50 moving average is 252.96 and the 200 day moving average is 286.31. The company has a market capitalisation of $187,622m. Find out more information at: https://www.danaher.com [stock_market_widget type="chart" template="basic" color="green" assets="DHR" range="6mo" interval="1d" axes="true" cursor="true" api="yf"] The potential market cap would be $243,046m based on the market concensus. Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company operates through three segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. The Life Sciences segment provides mass spectrometers; flow cytometry, genomics, lab automation, centrifugation, particle counting and characterization; microscopes; genomics consumables; and Gene and Cell Therapy.
Danaher Stock: A Much Needed Pullback (NYSE:DHR) 2022/07/03 09:42:27 Seeking Alpha
Danaher (DHR) is a Dividend Challenger with 8 consecutive years of dividend growth. DHR shares currently yield 0.39%. See why I am not purchasing DHR stock now.
IRW-PRESS: ACCESSWIRE News Network : OneMedNet Announces the Appointment of Dr. Christoph Zindel, Former Siemens AG and Beckman Coulter Executive, to its Board of Directors 2022/06/30 20:17:24 Boersen-Zeitung
MINNEAPOLIS, MN / ACCESSWIRE / June 30, 2022 / OneMedNet Corporation ("OneMedNet" or the "Company"), the leading curator of regulatory-grade Imaging Real Word Data, through its proven OneMedNet iRWD solution, today announced the appointment of Dr. Christoph Zindel to its Board of Directors. Dr. Zindel will be officially joining the board by October 1, 2022. Prior to his official appointment, Dr. Zindel agreed to serve on the board on a pro bono basis. Dr. Zindel, a noted industry executive, brings more than 30 years of diagnostic imaging, technology innovation, nuclear medicine and executive leadership experience and joins the board following a distinguished career including as President of Siemens Healthineers AG, where he served as Head of Diagnostic Imaging and served as a Member of the Managing Board at Siemens Healthineers AG. Currently, Dr. Zindel also serves as a Member of the Supervisory Board of Fresenius SE Group, and Senior Vice President, General Manager of Business Line Magnetic Resonance.
How Is The Market Feeling About Danaher? 2022/06/29 18:15:39 Benzinga
Danaher''s (NYSE: DHR ) short percent of float has fallen 7.35% since its last report. The company recently reported that it has 3.99 million shares sold short , which is 0.63% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.5 days to cover their short positions on average. Why Short Interest Matters Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price … Full story available on Benzinga.com